1332TiPTWO PHASE III STUDIES EVALUATING CERITINIB IN PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): ASCEND-4 AND ASCEND-5

1Massachusetts General Hospital, Boston, MA, USA; 2National Cancer Centre, Singapore, Singapore; 3Azienda Ospedale Perugia, Perugia; 4Vall d’Hebron University Hospital, Barcelona, Spain; 5Chinese University of Hong Kong, Shatin, China; 6The Cancer Institute Hospital of JFCR, Tokyo, Japan; 7Instituto de Investigaciones Biomedicas de Sevilla, University Hospital Virgen del Rocio, Seville, Spain; 8S. Luigi Hospital, University of Turin, Turin, Italy; 9Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA; 10University Hospital Cologne, Cologne, Germany; 11Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangzhou, China; 12Servico de Oncologia Clinica, Hospital das Clinicas da Faculdade de Medicina da USP, Sao Paulo, Brazil; 13Novartis Pharma, East Hanover, NJ, USA; 14Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France